What's with the Advanced Human Imaging (ASX:AHI) share price today?

The smartphone-based medical imaging company announces European approval for its AI skin scanner.

| More on:
dermatologist looking closely at the skin on a man's face

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in Advanced Human Imaging Ltd (ASX: AHI) are trading modestly today despite news the company's DermaScan AI has received European medical device approval. In earlier trade, the Advanced Human Imaging share price jumped more than 6% but has since retreated. At the time of writing, the company's shares are fetching $1.495, up 0.34%.

Today's news means the company's DermaScan AI device can now be used in 27 European Union (EU) countries.

Advanced Human Imaging developed the smartphone-based skin scanner in partnership with Canadian company Triage Technology Inc. It uses Triage's artificial intelligence (AI) technology to identify 588 skin conditions. The company claims the program is, on average, more effective than dermatologists.

Advanced Human Imaging also announced Triage has signed a distribution agreement with SkinHealth Canada. The agreement will see more than 2,000 Canadian healthcare professionals use the program.

Let's take a closer look at the news.

DermaScan AI approval

Having received EU approval, DermaScan AI will be available to more than 20,000 clinicians and dermatologists in Europe. It's already used by more than 20,000 medical professionals worldwide.

Advanced Human Imaging expects the technology will also receive US Food and Drug Administration approval later this year.  

The company plans to release DermaScan AI as a part of its smartphone-based CompleteScan platform in the third quarter of this year.

CompleteScan is a group of programs that use images from smartphone cameras to analyse a person's risk of health conditions and monitor existing health conditions.

Currently, the CompleteScan platform includes BodyScan and FaceScan. BodyScan analyses a person's body composition and chronic disease risk, while FaceScan analyses a person's vital signs, such as blood pressure, heart rate, and respiratory rate.

Once DermaScan AI is incorporated into CompleteScan, it will be available in 200 countries worldwide.

Commentary from management

Advanced Human Imaging CEO Vlado Bosanac commented on DermaScan AI's EU approval, saying:

This opens up the market significantly for AHI and Triage… More importantly it validates the Derma AI as credible, allowing medical practitioners access to the technology in their day-to-day practices… We are combining the Derma AI into the CompleteScan platform, which will allow our partner's users an ability to perform an extensive number of health checks via the CompleteScan platform.

Advanced Human Imaging share price snapshot

Advanced Human Imaging shares are having a strong year so far on the ASX.

Currently, the Advanced Human Imaging share price is sitting around 24% higher than it was at the end of 2020. It's also gained a whopping 740% since this time last year.

The company has a market capitalisation of around $204 million, with approximately 136 million shares outstanding.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »